A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Epeleuton (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Afimmune
- 05 Jul 2022 Status changed from suspended to discontinued.
- 12 Nov 2020 According to clinicaltrials.gov the study was stopped because of company's decision
- 12 Nov 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022.